Apple stores to stock chrome-plated glucose monitor from One Drop

The system features a predictive algorithm that forecasts glucose levels out to eight hours for Apple iOS users with type 2 diabetes, including those on oral medications or a basal insulin regimen. (Image: One Drop)

Apple, continuing its long march into healthcare, has begunstarted selling a fashionable, chrome-plated blood sugar monitor alongside its iPhones and Apple Watches in some of its U.S. retail stores. 

The glucose monitoring system, including a lancet, tester and strips, is developed by One Drop. It wirelessly syncs diabetes data with Apple’s devices and health apps, and had previously been available on the tech giant’s online storefront. 

Purchasers also receive one year of coaching via One Drop’s program, which includes digital tools for tracking medication, food intake and physical activity, and also offers test-strip subscription options. Apple had previously stocked Sanofi’s plug-in glucose meter for the iPhone, cleared in 2012. 

Webinar

Lipid-based Formulations for Early Stage Clinical Trials

Liquid-filled capsule technology has a proven record for addressing complex API formulation challenges, but also offers a simple and effective pathway to the clinic. Register now to learn more about lipid-based formulations.

"The healthcare industry is deeply invested in resisting progress, but consumerized, data-driven, digital health is becoming a reality," One Drop founder and CEO Jeff Dachis said in a statement

RELATED: Report: Study shows promise of Apple’s Health Records service

While not exactly a thrown sledgehammer, the system does feature a predictive algorithm that launched earlier this month, which forecasts glucose levels out to eight hours for Apple iOS users with type 2 diabetes, including those on oral medications or a basal insulin regimen.

RELATED: MannKind, One Drop to study Afrezza-app combo in Type 2 diabetes

One Drop says its machine learning-based predictions are powered by over 2.2 billion data points, collected from more than 1.2 million users. Alongside each forecast, users also receive advice on relevant behaviors for maintaining time-in-range.

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.